AFMD News and Press, Affimed N.V. From 04/12/22

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its p...

The shares of Affimed N.V. are trading lower in the post-market Tuesday after the German biotech announced an underwritten public offering of common stock. A 30-day option allowing underwriters to purchase up to an additional 15% of the shares of the common stock is also under consideration. ...

Shares of German cancer immunotherapy company Affimed (NASDAQ: AFMD) were up by a healthy 7.1% as of 11:59 a.m. ET Monday. The biotech's stock was flying higher in response to a positive clinical update for its lead blood cancer therapy, AFM13. AFM13 is a tetravalent bispeci...

Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...

Elon Musk's investment in Twitter (NYSE:TWTR) returned to the headlines in Monday's pre-market trading. Shares of the social media giant fell on news that the world's richest person won't join the company's board of directors, despite previous reports that he would. Elsewhere in the market, N...

The shares of Affimed (NASDAQ:AFMD) have added 13% in the pre-market Monday after the clinical-stage biotech announced a data update from an ongoing phase 1/2 study for its lead candidate in patients with certain blood cancer. The investigator-sponsored trial was designed to evaluat...

100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the recommended phase 2 dose (RP2D) Patients enrolled were multi-refractory with a median of seven prior lines of treatment; all Hodgkin...

Affimed experienced a four-month-long sell-off but has caught a bid following their full-year 2021 financial results, where they laid out a transformative 2022. Affimed expects to have three innate engagers in the clinic by the end of this year, which should deliver steady data flow o...

This a great market for stock pickers. Multiples have been cut in half for a lot of small-caps as the stock market has no appetite for risk right now. Nonetheless, if you do a lot of digging, you can find stocks with remarkable upside. Here's why our roundtable likes Affimed (NASD...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...